AbolerIS Pharma’s co-founder Dr. Carole Guillonneau receives Albert Sezary Prize from the National Academy of Medicine. 

Read the press release from December 15th, 2020.      

Read in French

Our Approach 

AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

schema aboleris -

Our Company

Founded in November 2019 by Dr. Carole Guillonneau (Director of Research CNRS) and Dr. Ignacio Anegon (Director of Research INSERM), researchers in Center of Research in Transplantation and Immunology (CRTI) UMR1064 INSERM/University of Nantes located at the Nantes University Hospital, together with Dr. François-Xavier Hubert (MD, PhD). AbolerIS Pharma is developing two innovative strategies to finely regulate the immune system: an anti-CD45RC monoclonal antibody and the cytokine IL-34.
AbolerIS Pharma received a pre-seed maturation funding from SATT Ouest-Valorisation and was incubated by Atlanpole Biotherapies, the regional competitiveness cluster.
In November 2020, Company raised a 2,5M$ in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé.


Dr. Carole GUILLONNEAU Advisor
PhD, Research Director class 2 at CNRS, director of an INSERM team at the Center for Research in Transplantation and Immunology CRTI.
Dr. Ignacio ANEGON
Dr. Ignacio ANEGONAdvisor
MD, Research Director class 1 at INSERM, Director of INSERM 1064 (2008-2018) and co-coordinator of team 2 “Induction of immunological tolerance”. Manager of the platform for genetically modified animals ” Rat Transgenesis and ImmunoPhenomic”.
Dr François-Xavier HUBERT
Dr François-Xavier HUBERT
MD, PhD in immunology. Advisor of international funding agencies and academic societies.

Scientific Advisory Board

Roland BUELOW (PhD)
Roland BUELOW (PhD)
Founder and CEO of Teneobio (Palo Alto, USA). Successful serial entrepreneur, 35 years’ experience in the generation of MAbs.
Hans-Dieter VOLK (MD)
Hans-Dieter VOLK (MD)
Charité, University of Berlin, 35 years of experience in translational and clinical immunology.
Michel GOLDMAN (MD, PhD)
Université Libre de Bruxelles, 38 years of research in translational immunology and academic-private pharmaceutical projects.